{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:48Z","timestamp":1786980108574,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03V0347"],"award-info":[{"award-number":["03V0347"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008791","name":"Bayer CropScience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The cell surface glycoprotein Mesothelin is overexpressed in ovarian, fallopian tube, endometrial, cervical and primary peritoneal cancer and, therefore, might become a particular interesting tumor target in gynecologic oncology. However, even in malignant tumors of the same entity the level of Mesothelin expression varies between individuals, hence it can be expected that the response to Mesothelin-targeting therapies will be variable as well. In this study we explored the therapeutic potency of a novel anti-Mesothelin antibody\u2013drug conjugate (Anetumab ravtansine) as a function of Mesothelin expression in the targeted tumor cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Anti-tumor activity studies were performed in human uterine xenograft tumor models that express Mesothelin at high, moderate or low levels. The antibody\u2013drug conjugate (ADC) was applied in varying doses ranging from 2 to 15\u00a0mg\/kg at variable intervals in tumor bearing SCID\/beige mice and the impact on tumor growth was monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The therapeutic response to the anti-Mesothelin ADC correlated closely with the level of Mesothelin expression in tumor cells. Within the applied dose levels complete tumor regression was achieved only in tumors which expressed Mesothelin at particularly high levels (Hela cell tumors). The application of high anti-Mesothelin ADC doses less frequently was more efficious than giving lower doses at a higher frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The studies confirm the great therapeutic potential of Anetumab ravtansine. However, a favorable treatment outcome requires strong Mesothelin expression in tumor cells. Future clinical trials may benefit from a more rigorous selection of appropriate patients based on the level of Mesothelin expression in their tumor tissue. If, in addition, it is possible to better control side effects by introducing protective measures and by doing so to increase the maximum tolerated dose, Anetumab ravtansine has the potency to become a valuable therapeutic tool, especially in the field of gynecological oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-020-05734-9","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T15:03:36Z","timestamp":1597849416000},"page":"1255-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Favorable therapeutic response after anti-Mesothelin antibody\u2013drug conjugate treatment requires high expression of Mesothelin in tumor cells"],"prefix":"10.1007","volume":"302","author":[{"given":"Lea","family":"Lazzerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korinna","family":"J\u00f6hrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4500-8108","authenticated-orcid":false,"given":"G\u00fcnter","family":"Cichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"issue":"1","key":"5734_CR1","first-page":"181","volume":"52","author":"K Chang","year":"1992","unstructured":"Chang K, Pai LH, Batra JK, Pastan I, Willingham MC (1992) Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 52(1):181\u2013186","journal-title":"Cancer Res"},{"issue":"1","key":"5734_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93(1):136\u2013140","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"5734_CR3","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","volume":"74","author":"I Pastan","year":"2014","unstructured":"Pastan I, Hassan R (2014) Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74(11):2907\u20132912","journal-title":"Cancer Res"},{"issue":"8","key":"5734_CR4","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","volume":"20","author":"TK Bera","year":"2000","unstructured":"Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20(8):2902\u20132906","journal-title":"Mol Cell Biol"},{"issue":"3","key":"5734_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.diff.2011.04.008","volume":"82","author":"T Kurita","year":"2011","unstructured":"Kurita T (2011) Normal and abnormal epithelial differentiation in the female reproductive tract. Differentiation 82(3):117\u2013126","journal-title":"Differentiation"},{"issue":"1","key":"5734_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","volume":"44","author":"R Hassan","year":"2008","unstructured":"Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer 44(1):46\u201353","journal-title":"Eur J Cancer"},{"issue":"34","key":"5734_CR7","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","volume":"34","author":"R Hassan","year":"2016","unstructured":"Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I (2016) Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 34(34):4171\u20134179","journal-title":"J Clin Oncol"},{"issue":"1","key":"5734_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00404-018-4933-z","volume":"299","author":"K J\u00f6hrens","year":"2019","unstructured":"J\u00f6hrens K, Lazzerini L, Barinoff J, Sehouli J, Cichon G (2019) Mesothelin as a target for cervical cancer therapy. Arch Gynecol Obstet 299(1):211\u2013216","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"5734_CR9","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1177\/030006051204000608","volume":"40","author":"Y Wang","year":"2012","unstructured":"Wang Y, Wang L, Li D, Wang HB, Chen QF (2012) Mesothelin promotes invasion and metastasis in breast cancer cells. J Int Med Res 40(6):2109\u20132116","journal-title":"J Int Med Res"},{"issue":"12","key":"5734_CR10","doi-asserted-by":"publisher","first-page":"e114900","DOI":"10.1371\/journal.pone.0114900","volume":"9","author":"G Tozbikian","year":"2014","unstructured":"Tozbikian G, Brogi E, Kadota K et al (2014) Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS ONE 9(12):e114900. https:\/\/doi.org\/10.1371\/journal.pone.0114900","journal-title":"PLoS ONE"},{"issue":"4","key":"5734_CR11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","volume":"20","author":"SS Kachala","year":"2014","unstructured":"Kachala SS, Bograd AJ, Villena-Vargas J et al (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20(4):1020\u20131028","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5734_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clbc.2013.05.001","volume":"13","author":"N Parinyanitikul","year":"2013","unstructured":"Parinyanitikul N, Blumenschein GR, Wu Y et al (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378\u2013384","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"5734_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jso.22024","volume":"105","author":"K Baba","year":"2012","unstructured":"Baba K, Ishigami S, Arigami T et al (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105(2):195\u2013199","journal-title":"J Surg Oncol"},{"issue":"75","key":"5734_CR14","doi-asserted-by":"publisher","first-page":"34103","DOI":"10.18632\/oncotarget.26135","volume":"9","author":"M Quanz","year":"2018","unstructured":"Quanz M, Hagemann UB, Zitzmann-Kolbe S et al (2018) Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget 9(75):34103\u201334121","journal-title":"Oncotarget"},{"issue":"4","key":"5734_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1248\/yakushi1947.118.4_111","volume":"118","author":"S Iwasaki","year":"1998","unstructured":"Iwasaki S (1998) Natural organic compounds that affect to microtubule functions. Yakugaku Zasshi 118(4):112\u2013126","journal-title":"Yakugaku Zasshi"},{"issue":"6","key":"5734_CR16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","volume":"13","author":"S Golfier","year":"2014","unstructured":"Golfier S, Kopitz C, Kahnert A et al (2014) Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13(6):1537\u20131548","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"5734_CR17","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jtho.2017.09.328","volume":"12","author":"HL Kindler","year":"2017","unstructured":"Kindler HL, Novello S, Fenell D et al (2017) Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma. J Thorac Oncol 12(11):1746 (Suppl. 2, abstract OA 02.01)","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5734_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11095-018-2533-z","volume":"36","author":"R Bucker","year":"2018","unstructured":"Bucker R, Schaefer C, Gruber AD et al (2018) Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma. Pharm Res 36(1):7","journal-title":"Pharm Res"},{"issue":"7","key":"5734_CR19","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/IGC.0000000000000179","volume":"24","author":"Y Lin","year":"2014","unstructured":"Lin Y, Yuxi W, Yuqin Y et al (2014) Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. Int J Gynecol Cancer 24(7):1158\u20131164","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"5734_CR20","first-page":"1031","volume":"50","author":"TW Griffin","year":"1990","unstructured":"Griffin TW, Collins J, Bokhari F et al (1990) Intraperitoneal immunconjugates. Cancer Res 50(3):1031\u20131038","journal-title":"Cancer Res"},{"issue":"11","key":"5734_CR21","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/BF00182351","volume":"21","author":"JG Tibben","year":"1994","unstructured":"Tibben JG, Massuger LF, Boermann OC, Claessens RA, Corstens FH (1994) Effect of route of administration on the biodistribution of radioiodinated OV-TL3 F (ab\u2019)2 in experimental ovarian cancer. Eur J Nucl Med 21(11):1183\u20131190","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"5734_CR22","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","volume":"32","author":"AV Kamath","year":"2015","unstructured":"Kamath AV, Iver S (2015) Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res 32(11):3470\u20133479","journal-title":"Pharm Res"},{"issue":"4","key":"5734_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/bc100498q","volume":"22","author":"X Sun","year":"2011","unstructured":"Sun X, Widdison W, Mayo M et al (2011) Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22(4):728\u2013735","journal-title":"Bioconjug Chem"},{"issue":"8","key":"5734_CR24","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson HK, Park PU, Widdison WC et al (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426\u20134433","journal-title":"Cancer Res"},{"issue":"19","key":"5734_CR25","doi-asserted-by":"publisher","first-page":"8999","DOI":"10.1073\/pnas.92.19.8999","volume":"92","author":"T Saga","year":"1995","unstructured":"Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, Weinstein JN (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92(19):8999\u20139003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9 Suppl","key":"5734_CR26","first-page":"2747s","volume":"52","author":"JN Weinstein","year":"1995","unstructured":"Weinstein JN, van Osdol W (2747s) Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the \u201cbinding site barrier\u201d. Cancer Res 52(9 Suppl):2747s\u2013s2751","journal-title":"Cancer Res"},{"issue":"19","key":"5734_CR27","first-page":"5144","volume":"52","author":"M Juweid","year":"1992","unstructured":"Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52(19):5144\u20135153","journal-title":"Cancer Res"},{"key":"5734_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M et al (2015) Tissue-based map of the human proteome. Science. https:\/\/doi.org\/10.1126\/science.1260419(PubMed: 25613900)","journal-title":"Science"},{"issue":"2","key":"5734_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","volume":"3","author":"XY Zhao","year":"2016","unstructured":"Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H (2016) Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs 3(2):76\u201386","journal-title":"Clin Cancer Drugs"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05734-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T19:31:31Z","timestamp":1629315091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05734-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5734"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05734-9","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Cichon received grant monies from Bayer AG. Prof. Sehouli receives funding for studies in ovarian cancer and serves on the Advisory Board as a consultant for Bayer. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal experiments were approved by the State Office for Health and Social Affairs (Berlin) in accordance with animal welfare regulations and valid ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}